Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

TMB-H 1Lymphoma, Extranodal NK-T-Cell 1Liver Neoplasms 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
IMC-001 × 90 days × Clear all
NCT04196465 2026-05-22

NeoChance

Asan Medical Center

Phase 2 Active not recruiting
48 enrolled
Gastrointestinal

Liver Neoplasms

NCT04414163 2026-04-24

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

ImmuneOncia Therapeutics Inc.

Phase 2 Active not recruiting
23 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT06365840 2026-04-17

TMB-H

ImmuneOncia Therapeutics Inc.

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

TMB-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡